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Abstract
The Rift Valley fever virus (RVFV) encodes the structural proteins nucleoprotein (N), aminoterminal glyco-
protein (Gn), carboxyterminal glycoprotein (Gc), and L protein, 78-kD, and the nonstructural proteins NSm and
NSs. Using the baculovirus system, we expressed the full-length coding sequence of N, NSs, NSm, Gc, and the
ectodomain of the coding sequence of the Gn glycoprotein derived from the virulent strain of RVFV ZH548.
Western blot analysis using anti-His antibodies and monoclonal antibodies against Gn and N confirmed ex-
pression of the recombinant proteins, and in vitro biochemical analysis showed that the two glycoproteins, Gn
and Gc, were expressed in glycosylated form. Immunoreactivity profiles of the recombinant proteins in western
blot and in indirect enzyme-linked immunosorbent assay against a panel of antisera obtained from vaccinated or
wild type (RVFV)-challenged sheep confirmed the results obtained with anti-His antibodies and demonstrated
the suitability of the baculo-expressed antigens for diagnostic assays. In addition, these recombinant proteins
could be valuable for the development of diagnostic methods that differentiate infected from vaccinated animals
(DIVA).
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Introduction
Rift Valley fever (RVF), caused by Rift Valley fever vi-rus (RVFV), represents a potential threat to global human
and animal health. The virus belongs to the genus Phlebovirus
of the family Bunyaviridae and causes severe epidemics
among ruminants and humans in Africa and the Arabian
Peninsula ( Jupp and Cornel 1988, Shoemaker et al. 2002).
Although the RVFV natural infection cycle has been linked to
the Aedes and Culex spp. mosquitos, other mosquito species,
including those found in North America, can be infected and
subsequently transmit the virus (McIntosh and Jupp 1981,
Gad et al. 1987, Gargan et al. 1988, Jupp and Cornel 1988,
Turell et al. 2010). The fact that a variety of mosquito species
can act as vectors increases the likelihood of RVFV becoming
endemic in areas outside of its traditional geographic range
(Turell et al. 1988). The potential risk of spread of RVFV to
temperate regions is exacerbated by global climate change,
the almost ubiquitous presence of potential mosquito vectors,
and international trade and travel. Currently, there are mul-
tiple challenges associatedwith efforts to combat RVF disease.
Most important amongst them are the development and
availability of an effective vaccine and pen-side diagnostic
assays. In Africa, a live attenuated vaccine based on the
Smithburn strain is available and provides lasting protective
immunity, but it is abortigenic in pregnant livestock (Smith-
burn 1949, Hunter, et al. 2002, Botros et al. 2006), thus limiting
its use. Killed or inactivated vaccines require multiple inocu-
lations to be efficacious, which poses logistical challenges in
developing countries where Rift Valley fever is endemic. The
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use of live-attenuated vaccines in nonendemic countries is less
desirable due to concerns of introduction of live RVFV into a
nonendemic region and the potential risk of reversion to vir-
ulence. Importantly, development of sensitive diagnostics, as
well as effective vaccines, will require the identification and
expression of sufficiently immunoreactive and potentially
immunoprotective proteins that could be used in diagnostic
assays or as candidates for vaccine development.
Like all members of the Bunyaviridae family, the RVFV
genome comprises three single negative-stranded RNA
strands, composed of large (L), medium (M), and small (S)
segments (Elliott 1996, Giorgi 1996, Schmaljohn 1996). The L
segment encodes the viral RNA-dependent RNA polymerase.
The M segment encodes the structural glycoproteins, Gn and
Gc, which are expressed as a polyprotein precursor that is
processed by cellular proteases during maturation (Collett
1986, Suzich et al. 1990, Gerrard and Nichol 2007). It has been
shown that these structural glycoproteins elicit production of
virus-neutralizing antibodies important for protective im-
munity (Niklasson et al. 1985, Besselaar and Blackburn 1994,
Bird et al. 2011, Papin et al. 2011, Piper et al. 2011). The M
segment also encodes a nonstructural protein, NSm, which
was shown to have an antiapoptotic function and a 78-kD
protein whose function is not known yet (Anderson and Pe-
ters 1988, Won et al. 2007). The S segment encodes the nu-
cleocapsid protein, N, and a nonstructural protein, NSs,
which is recognized as a major virulence factor of the virus
by counteracting host innate immunity (Vialat et al. 2000,
Bouloy et al. 2001, Billecocq et al. 2004, Le May et al. 2004). In
this study, we describe the expression of various RVFV pro-
teins using the baculovirus system and profile their reaction
pattern with antisera derived from RVFV vaccinated or
challenged sheep.
Materials and Methods
Cloning and construction of recombinant bacmid
The full-length coding sequences of the RVFV nucleopro-
tein (N) and the nonstructural protein (NSs) were amplified
by PCR using a proofreading DNA polymerase, Pfx50 (Life
Technologies/Invitrogen, Carlsbad, CA), and primers (Table
1) designed from published sequences of RVFV strain ZH548
(accession no. DQ380151). Plasmid pET30 Ek/LIC containing
the entire coding region of the S segment of ZH548 was used
as template for the PCR. The ectodomain and full-length
coding sequences of the virus structural glycoproteins Gne
and Gc, respectively, as well as the nonstructural M protein
NSm were synthesized according to the published sequences
of the ZH548 strain (Genewiz, San Diego, CA). Amplicons
were purified using a Qiagen gel or PCR purification kit
(Qiagen, Valencia, CA). The purified products were cloned
into a pFastBac/CT-TOPO vector (Life Technologies/
Invitrogen, Carlsbad, CA). The TOPO cloning reactions were
transformed into One Shot Mach1 T1 chemically competent
Escherichia coli to produce the respective donor plasmids pRF-
N, pRF-NSs, pRF-Gne, pRF-Gc, and pRF-NSm. The sizes and
sequences of the inserts in the donor plasmidswere confirmed
by PCR using gene-specific primers (Table 1) that were con-
firmed by restriction enzyme analysis and DNA sequencing.
Donor plasmids containing the gene of interest were purified
from the E. coli transformants using a Qiagen Miniprep kit
(Qiagen, Valencia, CA). The constructs were transformed
into MAX Efficiency DH10Bac-competent E. coli to generate
a recombinant bacmid by site-specific transpositioning. Re-
combinant bacmids were purified using HiPure Plasmid
Miniprep kit. Transpositioning of the gene of interest into a
recombinant bacmid was confirmed by PCR using M13F and
M13R primers (Heidecker et al. 1980).
Signal peptide prediction and modification
of Gn and Gc
The RVFV M segment, which encodes the envelope
glycoproteins Gn and Gc, has at least four translation ini-
tiation sites within the single mRNA transcribed from the
M segment. We hypothesized that sequences starting from
one of the initiation codons (ATG) to the start of Gn may
serve as a signal peptide and guide the translocation of the
polyprotein from the cytoplasm to the endoplasmic retic-
ulum (ER). Prediction of signal peptides and signal pepti-
dase cleavage sites was performed using hidden Markov
model and neural network model prediction programs at
SignalP 3.0. A 54-nucleotide sequence beginning from the
Table 1. Primers Used for the Amplification and Cloning of Rift Valley Fever Virus Protein-Coding Sequences
Primer Orientation Sequences Target/description Reference
JAR979 Forward CACCATGGACAACTATCAAGACCTTGCGATCC N cds Designed by this study
JAR980 Reverse GGCTGCTGTCTTGTAAGCCTGAGCG N cds Designed by this study
JAR981 Forward CACCATGGATTACTTTCCTGTGATATCTGTTGATTTG NSs cds Designed by this study
JAR982 Reverse ATCAACCTCAACAAATCCATCATCATCACTCTCC NSs cds Designed by this study
JAR975 Forward CACCATGATTGAAGGAGCTTGGGATTC NSm cds Designed by this study
JAR976 Reverse AGCAAAAACAACAGGTGCCAAAGC NSm cds Designed by this study
JAR996a Forward CACCATGACAGTCCTTCCAGCCTTAG Gne or Gc cds Designed by this study
JAR111 Reverse GGCACTGAGAGCAGTGTGACACTG Gne cds Designed by this study
JAR987 Reverse TGAGGCCTTCTTAGTGGCAGCAAG Gc cds Designed by this study
JAR990 Forward CCCAGTCACGACGTTGTAAAACG M13 sequencing
primer
Heidecker et al. 1980
JAR991 Reverse AGCGGATAACAATTTCACACAGG M13 sequencing
primer
Heidecker et al. 1980
aA signal peptide specific primer common for structural glycoproteins, Gne and Gc.
N, nucleoprotein; cds, coding sequence; NSs, nonstructural protein S; NSm, nonstructural protein m; Gne, ectodomain of Gn glycoprotein;
Gc, Gc glycoprotein.
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fifth ATG of the RVFV M segment, upstream of Gn coding
sequence, was identified as a strong signal peptide with a
single signal peptidase cleavage site. To ensure expression
of glycosylated forms of the proteins, this signal sequence
was fused to the amino terminus of Gne and Gc and am-
plified by PCR using primers shown in Table 1. The se-
quences were cloned into recombinant bacmids and
expressed in a baculovirus expression system (Life Tech-
nologies/Invitrogen, Carlsbad, CA).
Expression and purification
of recombinant RVFV proteins
To express recombinant RVFV proteins, highly purified
recombinant bacmids were transfected, using Cellfectin II
reagent (Life Technologies/Invitrogen Carlsbad, CA), into
Spodoptera frugiperda, Sf9, cells (Life Technologies/Invitro-
gen) grown in Sf-900 II SFM medium (Life Technologies/
Invitrogen, Carlsbad, CA) supplemented with 10% fetal
bovine serum (FBS) and 100U/mL–100 lg/mL penicillin–
streptomycin. Protein expression was carried out using P2 or
higher passage recombinant baculovirus stock (> 107 pfu/
mL) in T75 or T175 Biolite flasks (ThermoFisher Scientific,
Dubuque, IA). To visualize expression of recombinant pro-
teins, samples were subjected to western blot analysis by
resolving on 12% Bis-Tris polyacrylamide gel and detected
using anti-His-horseradish peroxidase (HRP) antibody.
Purification of recombinant proteins was carried out using
Ni-NTA superflow resin (Novagen, Rockland, MA) accord-
ing to manufacturer’s instructions. Recombinant proteins
were eluted with an elution buffer containing 300mM NaCl,
50mM Na2PO4 (pH 8.0), and 250mM imidazole and dia-
lyzed overnight against storage buffer, phosphate-buffered
saline (PBS; pH 7.4), and 5% glycerol. The purified proteins
were stained with Coomassie Blue, and protein concentra-
tions were determined using the bicinchoninic acid (BCA)
assay (Thermo Scientific, Rockford, IL) at an absorbance of
562 nm, using bovine serum albumin (BSA; Sigma-Aldrich,
St. Louis, Mo) as the protein standard. Aliquots were stored
at - 80C until used.
Immunofluorescence antibody assay
To confirm expression of recombinant RVFV proteins, we
carried out an immunofluorescence antibody assay. Briefly,
Sf9 cells were infected with recombinant baculovirus carrying
RVFV N- or Gne-coding sequences. About 36 h later, cells
were harvested and adhered to glass slides using a cytocen-
trifuge (Cytopro, Wescor, Logan, UT) according to manufac-
turer’s instruction and fixed in acetone for 5min at - 20C.
Slides were blocked in PBS containing 1% BSA at 37C for
45min and then incubated for 30min at 37C with mouse
monoclonal antibodies ID8 and 4D4 (provided by Dr. Connie
W. Schmaljohn, the United States Army Medical Research
Institute for Infectious Diseases, USAMRIID), against N and
Gn proteins, respectively. Slides were rinsed for 10min in 1·
fluorescence antibody (FA) rinse buffer (2.85 g Na2CO3, 8.4 g
NaHCO3, 2.125 g NaCl, distilled water to 1000mL; pH 9 to
9.5) and the probed with anti-mouse fluorescein isothio-
cyantate (FITC)-conjugated secondary antibody for 30min at
37C (Sigma-Aldrich, St. Louis, MO). Slides were rinsed
for 10min in 1· FA rinse buffer and counterstained with 4¢,6-
diamidino-2-phenylindole (DAPI; Invitrogen, Molecular
Probes) containing mounting medium. Slides were exam-
ined under a fluorescent microscope (Nikon, Eclipse 90i) at
100· magnification.
Tunicamycin assay
A baculovirus expression system was used to produce
glycosylated recombinant proteins, a posttranslational mod-
ification shown to enhance antigenicity/immunogenicity
(Gavrilov et al. 2011). To confirm that the modified Gne and
Gc proteins were glycosylated, a tunicamycin glycosylation
inhibition assay was performed. For this, six-well plates were
seeded with 2· 106 Sf9 cells per well and infected with re-
combinant baculoviruses expressing RVFV Gne or Gc at a
multiplicity of infection (MOI) of 1. Immediately following
infection, tunicamycin was added to each well at varying
concentrations of 0.5 lg/mL, 1 lg/mL, 3 lg/mL, 6lg/m,
8lg/mL, and 10lg/mL. Cells were harvested 5 days post-
infection (pi) and resuspended in PBS (pH 7.4) containing
1· Complete protease inhibitor (Roche Diagnostics, In-
dianapolis, IN). The samples were separated by sodium do-
decyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
in NuPAGE 12% Bis-Tris gels (Life Technologies/Invitrogen)
and transferred on to polyvinylidene difluoride (PVDF)
membranes (GE Healthcare, Amersham Hybond-P). The
membranes were probed as described above using anti-His
(carboxy-terminal)-HRP monoclonal antibody (Life Technol-
ogies/Invitrogen, Carlsbad, CA). Reactivity was detected
using the AEC (3-amino-9-ethyl-carbazole) peroxidase sub-
strate system (Abcam, Cambridge, MA).
Rift Valley fever virus anti-sera
Sheep (Rambouillet) were vaccinated subcutaneously with
106 plaque-forming units (pfu) of RVFV vaccine strain MP12.
These studies were performed at Kansas State University
(Biosecurity Research Institute [BRI] BSL-3Ag facility) or the
Arthropod-Borne Animal Diseases Research Unit (ABADRU)
large animal isolation building (LAIB) in Laramie,WY (day 28
sheep sera, P1–P6). Blood samples were collected from indi-
vidual animals at specific time points (days) postvaccination
(pv) for sera. Prevaccination blood samples were collected
from each individual sheep for use as preimmune control
sera. Day-28 pi antisera were obtained from previous sheep
challenged at the CFIA BSL-3Ag facility inWinnipeg, Canada,
with the wild-type RVFV ZH501 strain (sheep P7–P10). All
sera were stored at - 80C, and sera from the CFIA facility
were heat-inactivated with 0.5% Tween (56C for 30min)
prior to removal from the BSL-3Ag laboratory. Institutional
Animal Care and Use Committee (IACUC) protocols were
approved by Kansas State University and University of
Wyoming (ABADRU-LAIB).
Western blot analysis
Briefly, approximately 5lg of each of recombinant RVFV
protein was subjected to electrophoresis in 12% Bis-Tris
polyacrylamide gel in 1 · 3-(N-morpholino)propanesulfonic
acid (MOPS) running buffer (Life Technologies/Invitrogen).
The proteins were transferred by electroblotting onto PVDF
membranes according to standard protocols. The membrane
was blocked in 0.1% Tween-20 in PBS (pH 7.4) containing 3%
BSA at room temperature for 1 h. The blot was washed three
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times for 5min each in 0.1% Tween-20 in PBS. All subsequent
washing steps were carried out as described above. For
analysis of recombinant protein expression, the membrane
was incubated with anti-His(carboxyterminal)-HRP (Life
Technologies/Invitrogen) diluted 1:5000 in blocking solution.
Expression of recombinant proteins N and Gne was further
confirmed using a primary antibody, mouse anti-N (R3-ID8)
and mouse anti-Gn monoclonal antibody (4D4), respectively,
at a dilution of 1:2000. For analysis of reactivity against sheep
sera, the membrane was incubated with a 1:100 dilution of
each test serum for 1 h at room temperature. After washing,
the membrane was incubated for 1 h at room temperature
with Protein G–HRP (Abcam, Cambridge, MA) diluted
1:25,000. After the final washing steps, specific reactivity was
detected using AEC peroxidase substrate (Sigma-Aldrich, St.
Louis, MO).
Indirect enzyme-linked immunosorbent assay
A 96-well plate (Nunc, Maxisorp) was used for the indi-
rect enzyme-linked immunosorbent assay (ELISA). Each well
was coated overnight at 4C with 100 ng of recombinant
protein in 100 lL of Dulbecco’s coating buffer (pH 7.4) (Life
Technologies/Invitrogen). Plates were blocked for 15min at
37C with PBS (pH 7.4) containing 0.1% Tween and 1% skim
milk. After washing three times with 0.1% Tween-20 in PBS, a
volume of 200 lL of test serum, diluted 1:200 in the blocking
solution, was added and incubated at 37C for 1 h. All sub-
sequent washing steps were carried out three times as indi-
cated above. Each serum sample was tested in duplicate.
Each test included a positive control, obtained from sheep
challenged with a virulent strain of RVFV (ZH501), and
negative controls obtained from the respective sheep prior to
vaccination.
After washing, plates were incubated with Protein G–HRP
(Abcam, Cambridge, MA), diluted 1: 50,000 in blocking so-
lution, at 37C for 1 h. Protein G has high binding affinity to
immunoglobulin (IgG) from sheep, goats, horses, and rabbits,
with little or no binding affinity to IgM. After washing, 100 lL
of substrate buffer containing 0.1mg/mL 3,3¢,5,5¢-tetra-
methylbenzidine (TMB) (Thermo Scientific, Rockford, IL) and
hydrogen peroxide (H2O2) was added and the plates were
incubated in the dark for 25min. The reaction was stopped
with 2MH2SO4, and optical densities (OD) were measured at
450 nm using a microplate reader (Fluostar Omega, BMG
Labtech, Cary, NC). For each ELISA, the cutoff OD value was
determined by addition of 2 standard deviations (SD) to the
mean OD value of serum obtained from prevaccinated/non-
infected sheep.
Statistical analysis
Data were analyzed using a t-test of independent samples
with equal or unequal variances. To reduce the effect of var-
iable individual host immune response on reactivity, we cal-
culated geometric means of OD values and analyzed the
differences for statistical significance.
Results
Expression of RVFV recombinant proteins
Using recombinant baculovirus, RVFV structural (Gc, Gn,
and N) and nonstructural (NSs and NSm) proteins, each
containing a hexahistidine tag at their carboxyl terminus,
were expressed in a eukaryotic expression system using Sf9
cells. To ensure translocation in the ER and glycosylation of
the structural glycoproteins Gne and Gc, a signal peptide was
fused upstream of the amino terminus of both proteins. In-
fection of Sf9 cells with recombinant baculovirus carrying the
full-length Gn coding sequence resulted in no or a low
amount of Gn protein. To minimize interactions of the full-
length Gn with cellular membranes, only the ectodomain of
the protein Gne, without the transmembrane and cytosolic
regions, was expressed. The proteins were purified and
detected by western blot using anti-His-HRP monoclonal
antibody (Fig. 1A). Recombinant proteins of the expected
molecular weights were expressed (Gc, 60 kD; Gne, 54 kD; N,
30 kD; NSs, 33 kD; NSm, 17 kD). Expression of N and Gn
proteins was further confirmed by immunoreaction with anti-
N or anti-Gn mouse monoclonal antibodies (Fig. 1B).
Coomassie-stained gels of the purified proteins are shown in
Figure 1C. Immunofluorescent antibody assay using the
mouse monoclonal antibodies against the Gn and N proteins
further confirmed the expression of the proteins in Sf9 cells
(Fig. 2). A specific green immunofluorescent signal was ob-
served around the periphery of the nucleus of Gne-expressing
cells, whereas N appeared to show a more diffuse staining
(Fig.2).
Baculovirus-expressed Gn and Gc proteins
are N-glycosylated
It is known that the RVFV Gn and Gc glycoproteins carry
one and four putative N-glycosylation sites, respectively
(Gerrard and Nichol 2007). To characterize glycosylation
patterns of Gne and Gc, biochemical inhibition of N-glyco-
sylation by treatment of cells with tunicamycin, a potent in-
hibitor of bacterial and eukaryote N-acetylglucosamine
transferases, was carried out. Treatment of Sf9 cells infected
with either recombinant Gc or Gne baculoviruses with vary-
ing concentrations of tunicamycin (0.5–10lg) resulted in in-
hibition of glycosylation of the proteins demonstrated by a
lower molecular weight of the reactive proteins when com-
pared to nontreated controls. The shift was more obvious for
Gc (Fig. 3A), known to have four putative glycosylation sites
when compared to Gne (showing marginal shift), known to
have only one glycosylation site (Fig. 3B). As a control, ba-
culovirus-expressed sheep prion protein (PrP) expressed in
Sf9 cells was used. Treatment with tunicamycin resulted in
significant inhibition of N-glycosylation (Fig. 3C).
Western blot analysis
We examined antibody reactivity against the recombinant
proteins N, NSs, NSm, Gne, and Gc using sera collected at
different time points pv (days 3, 10, and 28) from MP12 vac-
cinated sheep. Recombinant N was reactive with day-3 pv
sera, and bothN andNSs proteins showed antibody reactivity
with day-10 pv and day-28 pv sera, with N showing consis-
tently stronger reactivity than NSs (Fig. 4). Reactivity of the
structural glycoproteins Gne and Gc showed that Gne was
reactive with 1 of 2 serum samples on day 3pv. Thereafter, it
remained consistently reactive with all sera obtained on day
10 and 28pv (Table 2). The Gc protein showed no reactivity at
day 3pv and weak reactivity with day 10pv sera, where only
1 of the 4 serum samples tested was positive; it was 90%
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reactive with day 28pv sera. To examine reactivity of RVFV
proteins further, we performed immunoblot analysis using
day-28 pi sera obtained from sheep infected with the wild-
type strain ZH501 of RVFV. Recombinant N and Gne proteins
showed consistent and strong reactivity against all sera (4/4);
NSs and Gc were also reactive against all sera (4/4) but
with relative lower signal intensities. We did not detect spe-
cific reactivity with the NSm protein, either with the MP12-
vaccinated or ZH501-infected sheep sera.
Indirect ELISA
An indirect ELISA was developed to assess antibody re-
activity of the recombinant proteins against sera obtained
from sheep vaccinated with RVFV MP12 vaccine strain or
challenged with wild-type ZH501 RVFV strain. For MP12-
vaccinated sheep sera, the recombinant proteins N, NSs, Gc,
and Gne showed time-dependent increase in reactivity,
shown by an increase in OD values (Fig. 5A–D). A consistent
strong reactivity for all proteins was observed with day-28
sera. There was particularly strong antibody reactivity with N
and to a lesser extent with Gne on day 3 pv (Fig. 5A, C). The
level of reactivity with NSs was also strong but had com-
paratively lower OD values (Fig. 5B). Reactivity with Gc was
high on day 10 pv and was strongest on day 28 (Fig. 5D). For
the wild type exposure-derived sheep sera, the recombinant
proteins, N, NSs, Gne, andGcwere reactive with the day 28 pi
(data not shown). In contrast, NSm showed low reactivity
manifested by relatively low OD values with sera from both
MP12 and wild-type infected sheep (Fig. 5E). Sera from three
sheep (infected with the wild-type ZH501, P7 and P10, and
FIG. 2. Immunofluorescence antibody assay confirms ex-
pression of the recombinant proteins Gne and N in Sf9 cells.
Monoclonal antibodies 4D4 and ID8 were used to detect
expression of Gne and N, respectively. A specific green
fluorescent signal around the nucleus of Gne-expressing cells
is seen indicating that the recombinant protein is within the
cell. Anti-Gn control, noninfected Sf9 cells stained with Gn
monoclonal antibody (4D4); anti-N control, noninfected Sf9
cells stained with N monoclonal antibody (ID8) show nega-
tive staining. The cell nucleus is stained in blue color.
FIG. 1. Baculovirus-expressed Rift Valley fever virus (RVFV) proteins. Proteins were purified and detected using anti-His(C-
term)HRPmonoclonal antibody. Gne, 54kD; Gc, 60kD; NSs, 34kD; N, 31 kD;NSm, 14kD;M,marker (A). Monoclonal antibodies
against N andGn, IDE8 and 4D4, respectively, were used to confirm expression of the respective proteins (B). (C) Coomassie Blue
staining of the purified proteins. N, nucleoprotein; NSs, nonstructural protein S segment; NSm, nonstructural proteinm segment;
Gne, ectodomain of amino-terminal glycoprotein; Gc, carboxy-terminal glycoprotein; M, molecular weight marker.
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MP-12-immunized sheep, P5) showed significant reactivity
( p< 0.05) in comparison with the negative control (day 0 se-
rum). The positive serawere obtained from sheep on day 28pi
with the wild-type RVFV ZH501.
Discussion
There is increasing demand for sensitive and safe diag-
nostic tests and efficacious vaccines for zoonotic pathogens,
including RVFV, to protect human and animal health.
The recent spread of RVFV beyond its traditional endemic
boundaries in Africa to the Arabian Peninsula ( Jupp and
Cornel 1988, Ikegami and Makino 2009, Abdo-Salem
et al. 2011) has resulted in increased interest for RVFV
vaccines, rapid diagnostics, and associated immuno-
reagents. At present, diagnosis of RVFV infection is
achieved using various techniques including virus isolation
(Shope and Sather 1979, Anderson et al. 1989), antigen de-
tection (Niklasson et al. 1983, Meegan et al. 1987, Drolet
et al. 2012), nucleic acid amplification techniques (Ibrahim
et al. 1997, Garcia et al. 2001, Drosten et al. 2002, Drolet
et al. 2012), and detection of RVFV-specific antibodies
(Niklasson et al. 1984, Swanepoel et al. 1986, Meegan et al.
1987, Paweska et al. 2003).
The use of virus isolation is not user-friendly, takes an ex-
tended period of time, and requires suitable biosafety proto-
cols or measures; antigen or nucleic acid detection in the
serum or blood of animals or humans only works in cases of
host viremia, which in the case of RVFV infection is a narrow
viremic window, lasting on average about 3 days in serum
(Morrill et al. 1990, Nfon et al. 2012, Smith et al. 2012) or
longer in whole blood (Grolla et al. 2012). The classical
methods for detection of antibodies to RVFV include various
forms of virus neutralization and hemagglutination-inhibi-
tion tests. Disadvantages of these techniques include health
risk to laboratory personnel (Smithburn 1949), as well as re-
strictions to high biocontainment laboratories for their use
outside RVF endemic areas (Barnard 1979).
FIG. 3. In vitro glycosylation assay of Rift Valley fever glycoproteins, Gc and Gne. (A) Treatment of Gc-recombinant
baculovirus-infected Sf9 cells with varying concentrations of tunicamycin (0.5 lg/mL to 10lg/mL) resulted in inhibition of
glycosylation shown by a shift in electrophoretic migration. (B) Similar treatment of Gne (8lg/mL and 10 lg/mL) resulted in
marginal molecular weight shift (compare with nontreated, nt), since the protein has one putative N-glycosylation site; Gc has
four putative N-glycosylation sites. Treatment of baculovirus expressed sheep prion protein (PrP) with varying concentra-
tions of tunicamycin (1lg/mL to 10 lg/mL) resulted in inhibition of glycosylation of the protein(C). nt, nontreated controls;
m, molecular weight marker.
FIG. 4. Western blot showing a sample of immunoreac-
tivity of purified baculovirus-expressed proteins with RVFV
antisera from sheep. Reactivity shows that the proteins were
expressed in the correct conformation. Gne, ectodomain of
amino-terminal glycoprotein; N, nucleoprotein; NSs, non-
structural protein S segment; Gc, carboxy-terminal glyco-
protein; CL, noninfected cell lysate; m, molecular weight
marker; pv, postvaccination; pi, postinfection.
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On the other hand, application of ELISA to detect IgG an-
tibody to RVFV relied largely on the use of inactivated whole
virus lysate, which is also associated with potential health
risks (Swanepoel et al. 1986a, Swanepoel et al. 1986b, Meegan
et al. 1987, Paweska et al. 1995). The nucleocapsid (N) protein
is the most abundant and highly immunogenic component of
the RVF virion and has been used for development of diag-
nostic assays for detection of RVFV-specific antibodies in
human and animal sera (Fafetine et al. 2007, Jansen van Vuren
et al. 2007, Paweska et al. 2007, Paweska et al. 2008). Although
the N protein is shown to be highly conserved among mem-
bers of the Bunyaviridae family (Schwarz, et al. 1996, Ma-
gurano and Nicoletti 1999), a previous indirect ELISA based
on the recombinant protein did not show cross-reactivity with
other African phleboviruses that could hamper the reliability
of using this protein in assays for serodiagnosis of RVFV
Table 2. Reactivity of Baculovirus-Expressed Rift Valley Fever Virus Proteins
with Sheep Antisera Determined by Western Blot
MP12 vaccinated sheep sera: days pv
Day 10Recombinant
proteins Day 3 (nsp/total sample tested) Day 28
Wild type (ZH501) challenged sheep sera:
day 28 pi (nsp/total sample tested)
Gne 1/2 4/4 10/10 4/4
Gc 0/2 1/4 9/10 4/4
N 2/2 4/4 10/10 4/4
NSs 0/2 4/4 9/10 4/4
NSm 0/2 0/4 0/10 0/4
pv, postvaccination; pi, postinfection; nsp, number of samples tested positive; Gne, ectodomain of Gn glycoprotein; Gc, Gc glycoprotein; N,
nucleoprotein; NSs, nonstructural protein S; NSm, nonstructural protein m.
FIG. 5. Reactivity of recombinant RVFV proteins, nucleoprotein, N (A), nonstructural protein, NSs (B), glycoprotein, Gne
(C), glycoprotein, Gc (D), and nonstructural protein NSm (E) with antisera from MP12 vaccinated sheep. Day 0, pre-
vaccination sera; PC, positive control sera derived from sheep challenged with RVFV wild-type, ZH501; P1–P6, day-28 sera
from sheep vaccinated with MP12 RVFV strain (Laramie, WY); P7–P10, day-28 sera from sheep infected with the wild-type
virus (ZH501). Asterisks (*) denote level of statistical significance and show that differences in optical density (OD) values of
sera tested for each of the time-points was significantly different ( p < 0.05) from day 0 (prevaccination) sera. Cutoff OD value
for each enzyme-linked immunosorbent assay (ELISA) was determined by addition of 2 standard deviations to the mean OD
value of serum obtained from prevaccinated/noninfected sheep. N, 0.320; NSs, 0.358; Gn, 0.395; Gc, 0.387; NSm, 0.208.
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infection (Paweska et al. 2007). However, the N protein did
show serological cross-reactivity with an unidentified agent
among some sera from US and Canadian sheep (Wilson et al.,
personal communication).
Recombinant proteins provide a safe platform for devel-
opment of improved diagnostics and, in some cases, for
subunit vaccines. In this study, we have expressed a panel of
RVFV proteins (N, NSs, NSm, Gne, and Gc) using the bacu-
lovirus expression system and evaluated their potential as
diagnostic targets. One of the advantages of using the bacu-
lovirus expression system is the ability to scale up expression;
it also allows posttranslational protein modification, which in
the case of glycoproteins, enhances antigenicity and immu-
nogenicity. Sequence modifications made to Gn and Gc re-
sulted in enhanced expression, and analysis of Gne expression
by immunofluorescence showed that the protein was present
within the cell, manifested by detection of green fluorescence
around the cell nucleus, in the periphery of the plasma
membrane of infected cells (Fig. 2).
Indeed, other studies reported specific targeting of recom-
binant RVFV glycoproteins to the plasma membrane of insect
cells using the baculovirus expression system (Takehara et al.
1990, Liu et al. 2008) or localization of the proteins on the cell
surface when expressed using alphavirus replicons (Filone
et al. 2006). To ensure that Gne and Gc, are translocated into
the ER and glycosylated, we added a signal peptide sequence
carrying a signal peptidase cleavage site upstream of the 5¢
end of the coding sequence. This ensured correct protein
trafficking through the lumen of the ER, where glycosylation
enzymes and signal peptidase are located (Gerrard and
Nichol 2002, Gerrard and Nichol 2007). Biochemical charac-
terization of glycosylation of Gne and Gc showed that
the glycoproteins were N-glycosylated. Treatment with tuni-
camycin, a potent inhibitor of bacterial and eukaryote
N-acetylglucosamine transferases, resulted in inhibition of
glycosylation as detected by electrophoretic migration of the
proteins (Fig. 3A, B), strongly indicating that Gne andGcwere
subjected to posttranslational N-glycosylation.
Analysis of antibody reactivity of the recombinant proteins
with RVFV antisera by western blot and indirect ELISA
showed the proteins were immunoreactive, a strong indica-
tion of correct structural conformation. In western blot ana-
lyses (Fig. 4) and ELISA (Fig. 5) using MP12 vaccinated and
wild-type–challenged sera, the RVFV nucleocapsid protein
was the most reactive. As the most abundant and highly im-
munogenic structural component of RVFV virion, the N
protein has been considered the best choice for the develop-
ment of immunoreagents for antigen detection assays (Pepin
et al. 2010).
The early immune response and strong antibody reactivity
against N protein with MP12-vaccinated sera might suggest a
possible role of N protein in protective immunity to RVFV
infection. Indeed, vaccination with N antigen has been shown
to protect mice fromwild-type RVFV challenge (Wallace et al.
2006, Liu et al. 2008, Lorenzo et al. 2008, Lagerqvist et al. 2009,
Jansen van Vuren et al. 2010, Lorenzo et al. 2010). Re-
markably, the glycoprotein Gne also showed an early-re-
sponse reactivity (day 3pv) in western blot and ELISA with
MP12-vaccinated sera and was detected by day-28 pi sera
from all ZH501-infected sheep. This would qualify Gne, in
addition to the N-protein, as a good choice as a diagnostic
antigen.Moreover, the early and specific antibody response to
Gne found with MP12-vaccinated sheep makes this protein a
good candidate for vaccine development. Importantly, the
RVFV glycoproteins Gne and Gc have been shown to contain
epitopes that induce production of neutralizing antibodies, a
correlate of protective immunity against RVFV infection
(Niklasson et al. 1985, Morrill et al. 1987, Hubbard et al. 1991,
Morrill et al. 1997).
Therefore, future studies should aim at establishing a
possible correlation between Gne reactivity and the presence
of neutralizing antibodies. Also, baculovirus-expressed re-
combinant Gne alone or in combination with recombinant N
could improve the sensitivity and specificity of herd screen-
ing for RVFV infections in areas where cross-reactivity with
other bunyaviruses/phleboviruses may be an issue. Re-
combinant Gc also showed strong reactivity with sheep sera,
but seemed to be less sensitive when compared with Gne
(Fig. 5). However, the induction of a strong antibody re-
sponse to Gc appears later in MP12-vaccinated animals
compared to N and Gn. For improved RVFV detection,
molecular tools for detection of RVFV nucleic acids should
be used in parallel with antibody detection to identify early-
infected ruminants.
The recombinantNSs protein showed early-onset reactivity
with MP12 sera, but had an overall lower reactivity than the
FIG. 5. (Continued).
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N protein. This may be attributed to the typically low anti-
body titers raised against the NSs protein after RVFV infec-
tions (Pepin et al. 2010). The RVFV NSs protein is responsible
for general suppression of the host transcriptional machinery,
including type I interferons (Le May et al. 2004, Le May et al.
2008). In contrast to NSs, the other nonstructural protein,
NSm, showed poor reactivitywith sera fromMP12 vaccinated
and wild-type–challenged animals in western blot. Further
assessment of its reactivity in an ELISA test showed little or no
reactivity with MP12-vaccinated sera, demonstrated by ex-
tremely low OD values (Fig. 5E). Sera from 3 sheep (2 wild
type–infected, P7 and P10, and 1MP12-vaccinated, P5), at day
28 pi showed relatively high reactivity when compared to
day-0 sera (Fig. 5E). Interestingly, in a virulent RVFV chal-
lenge experiment using ELISA, Bird et al. (2011) reported se-
ropositivity for NSs antibodies in all 3 control sheep, whereas
only 2 of the 3 animalswere seropositive for NSm; this was the
first time immunoreactivity against NSmhad been detected in
a natural host species (Bird et al. 2011). This might indicate
that NSm is less immunogenic when compared to NSs or is
expressed at lower levels resulting in a lower antibody re-
sponse in mammalian hosts.
The development of a diagnostic tool that differentiates
infected from vaccinated animals (DIVA) is very much nee-
ded in regions nonendemic for RVFV. The apparent poor
immunogenicity of RVFV NSm in ruminant hosts reported in
this paper and also shown previously (Bird et al. 2011) makes
the use of NSm as a target for developing a DIVA diagnostic
test questionable. In this study, NSs-specific antibodies were
consistently detected in RVFV-infected/vaccinated sheep,
which suggests that the NSs protein may serve as a candidate
for the development of a DIVA diagnostic assay. Previous
investigators have demonstrated variability of detection of
antibodies to NSs (Fernandez et al. 2012). Therefore, further
optimization and standardization of the use of this protein in
diagnostic assays may be required for this antigen to be a
reliable DIVA marker.
Research efforts aimed at the development and valida-
tion of a new generation of safe and accurate diagnostic
immunoreagents and assays based on RVFV recombinant
antigens are critical (Pepin et al. 2010). This is the first
study to carry out expression of several RVFV proteins and
assess their reactivity against a panel of immune sera from
natural hosts. Analysis of antibody reactivity revealed that
the proteins were expressed in the correct conformation in
a baculovirus expression system. Addition of a fusion sig-
nal peptide sequence to the structural glycoproteins Gne
and Gc ensured processing of the proteins through the
cellular glycosylation pathway. We have shown that ba-
culovirus-expressed N, Gne, Gc, and NSs could be used as
potential serodiagnostic targets for monitoring host hu-
moral immune response to infection and/or vaccination.
The immunoreactivity toward NSm was rather weak
making this RVFV antigen a less desirable diagnostic tar-
get. The general immunoreactivity profile suggests that N
and Gne would represent desirable targets for development
of highly sensitive serodiagnostic assays. In addition, fu-
ture vaccine formulations will require DIVA compatibility
with companion diagnostic DIVA tests. We have shown
that baculovirus-expressed N and NSs assays, depending
on the vaccine composition, can be used for such com-
panion assays.
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